# Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)

> **NCT00202865** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 76 (actual)

## Conditions studied

- Spondylitis, Ankylosing

## Interventions

- **BIOLOGICAL:** infliximab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00202865
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05-01
- **Primary completion:** 2007-05-01
- **Final completion:** 2007-05-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2017-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00202865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00202865, "Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00202865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*